C Aaron Smith1, Haddon Smith1, Lisa Roberts2, Lori Coward3, Gregory Gorman1,3, Amrisha Verma4, Qiuhong Li4, Thomas W Buford2,5, Christy S Carter2, Patricia Jumbo-Lucioni1,6. 1. McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA. 2. Department of Medicine; Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Pharmaceutical Sciences Research Institute, Samford University, Birmingham, AL, USA. 4. Department of Ophthalmology, College of Medicine, University of Florida Gainesville, FL, USA. 5. Geriatric Research Education and Clinical Center, Birmingham VA Medical Center, Birmingham, AL, USA. 6. Department of Biology, College of Arts and Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract
BACKGROUND: While extensive research on the brain has failed to identify effective therapies, using probiotics to target the gut microbiome has shown therapeutic potential in Alzheimer's disease (AD). Genetically modified probiotics (GMP) are a promising strategy to deliver key therapeutic peptides with high efficacy and tissue specificity. Angiotensin (Ang)-(1-7) levels inversely correlate to AD severity, but its administration is challenging. Our group has successfully established a GMP-based method of Ang-(1-7) delivery. OBJECTIVE: Since Drosophila represents an excellent model to study the effect of probiotics on complex disorders in a high throughput manner, we tested whether oral supplementation with Lactobacillus paracasei releasing Ang-(1-7) (LP-A) delays memory loss in a Drosophila AD model. METHODS: Flies overexpressing the human amyloid-β protein precursor and its β-site cleaving enzyme in neurons were randomized to receive four 24-h doses of Lactobacillus paracasei alone (LP), LP-A or sucrose over 14 days. Memory was assessed via an aversive phototaxic suppression assay. RESULTS: Optimal dilution,1:2, was determined based on palatability. LP-A improved memory in trained AD males but worsened cognition in AD females. LP-supplementation experiments confirmed that Ang-(1-7) conferred additional cognitive benefits in males and was responsible for the deleterious cognitive effects in females. Sex-specific differences in the levels of angiotensin peptides and differential activation of the kynurenine pathway of tryptophan metabolism in response to supplementation may underlie this male-only therapeutic response. CONCLUSION: In summary, LP-A ameliorated the memory deficits of a Drosophila AD model, but effects were sex-specific. Dosage optimization may be required to address this differential response.
BACKGROUND: While extensive research on the brain has failed to identify effective therapies, using probiotics to target the gut microbiome has shown therapeutic potential in Alzheimer's disease (AD). Genetically modified probiotics (GMP) are a promising strategy to deliver key therapeutic peptides with high efficacy and tissue specificity. Angiotensin (Ang)-(1-7) levels inversely correlate to AD severity, but its administration is challenging. Our group has successfully established a GMP-based method of Ang-(1-7) delivery. OBJECTIVE: Since Drosophila represents an excellent model to study the effect of probiotics on complex disorders in a high throughput manner, we tested whether oral supplementation with Lactobacillus paracasei releasing Ang-(1-7) (LP-A) delays memory loss in a Drosophila AD model. METHODS: Flies overexpressing the human amyloid-β protein precursor and its β-site cleaving enzyme in neurons were randomized to receive four 24-h doses of Lactobacillus paracasei alone (LP), LP-A or sucrose over 14 days. Memory was assessed via an aversive phototaxic suppression assay. RESULTS: Optimal dilution,1:2, was determined based on palatability. LP-A improved memory in trained AD males but worsened cognition in AD females. LP-supplementation experiments confirmed that Ang-(1-7) conferred additional cognitive benefits in males and was responsible for the deleterious cognitive effects in females. Sex-specific differences in the levels of angiotensin peptides and differential activation of the kynurenine pathway of tryptophan metabolism in response to supplementation may underlie this male-only therapeutic response. CONCLUSION: In summary, LP-A ameliorated the memory deficits of a Drosophila AD model, but effects were sex-specific. Dosage optimization may be required to address this differential response.
Authors: Armando Reyes-Engel; Luis Morcillo; Francisco Javier Aranda; Maximiliano Ruiz; Maria Jesús Gaitan; Alvaro Mayor-Olea; Pedro Aranda; Carlos Maria Ferrario Journal: J Renin Angiotensin Aldosterone Syst Date: 2006-06 Impact factor: 1.636
Authors: M J Cornell; T A Williams; N S Lamango; D Coates; P Corvol; F Soubrier; J Hoheisel; H Lehrach; R E Isaac Journal: J Biol Chem Date: 1995-06-09 Impact factor: 5.157
Authors: Sonali A Deshpande; Gil B Carvalho; Ariadna Amador; Angela M Phillips; Sany Hoxha; Keith J Lizotte; William W Ja Journal: Nat Methods Date: 2014-03-30 Impact factor: 28.547
Authors: Riccardo Calvani; Anna Picca; Maria Rita Lo Monaco; Francesco Landi; Roberto Bernabei; Emanuele Marzetti Journal: Front Med (Lausanne) Date: 2018-03-02